Rheumatologist User Base for Eli Lilly’s Taltz in Psoriatic Arthritis (PsA) Boasts Strong Growth in Q2, While Use of Pfizer’s Xeljanz Has Remained Flat Over the Past Quarter
Download Report Overview EXTON, Pa., July 17, 2018 /PRNewswire/ — The most recent quarterly results of a study conducted by Spherix Global Insights with 100 US rheumatologists reveals that the user-base for Eli Lilly’s Taltz has more than doubled since the first quarter of 2018 while use of Pfizer’s Xeljanz has remained relatively flat after […]
TNF Cycling in Psoriatic Arthritis Declines for the Second Year in a Row as Newly Approved Agents Such as Pfizer’s Xeljanz and Eli Lilly’s Taltz Claim Their Share of the Switching Population
According to Spherix Global Insights, data from over 1,000 psoriatic arthritis patients who recently switched therapies reveals that clinical factors, such as joint and skin efficacy, often drive the decision to switch, while non-clinical factors often influence the choice of the new brand. Download Report Overview EXTON, Pa., May 30, 2018 /PRNewswire/ — With four […]
Warning to Eli Lilly’s Olumiant (baricitinib): Entrenched First-to-Market Rheumatoid Arthritis Products are Tough to Unseat
After a year on the market, Sanofi/Regeneron’s Kevzara has had little success overthrowing Roche/Genentech’s Actemra as the go-to IL-6 inhibitor for treating rheumatoid arthritis (RA) Download Report Overview EXTON, Pa., May 10, 2018 /PRNewswire/ — According to Spherix Global Insights’ second quarter update of RealTime Dynamix™: Rheumatoid Arthritis (US), at just under one-year post-launch, less […]
Pfizer’s Xeljanz Barrels into Psoriatic Arthritis, Leaving Lilly’s Recently Launched Taltz in its Wake, According to a Recently Published Study from Spherix Global Insights
Janssen’s Simponi Aria and BMS’ Orencia seem to be settling into their respective niches, but neither brand is anticipated to bring much disruption to the PsA market Download Report Overview EXTON, Pa., April 9, 2018 /PRNewswire/ — The most recent quarterly results of a study conducted by Spherix Global Insights with 101 US rheumatologists reveals […]
As Lilly Deals with Yet Another Set-Back in Entering the US Rheumatoid Arthritis Market, Pfizer’s Xeljanz Further Solidifies Its Position as a Go-To Alternate Mechanism of Action Agent, According to a Recently Published Study by Spherix Global Insights
Though baricitinib (Olumiant) has been resubmitted for FDA approval, time lost on the US market has opened up doors for Xeljanz Download Report Overview EXTON, Pa., Feb. 20, 2018 /PRNewswire/ — Since receiving a Complete Response Letter from the FDA for their Incyte partnered investigational JAK 1/2 inhibitor, baricitinib (Olumiant), Eli Lilly’s entrance into the […]
JAK Inhibitors Expected to Introduce Fierce Competition to Treatment Paradigms Across a Wide Range of Autoimmune Indications, Including Psoriatic Arthritis, Atopic Dermatitis, Ulcerative Colitis, and Lupus
Recent milestones include Pfizer’s Xeljanz approval for PsA in December, the pending review of Xeljanz in UC expected in mid-2018, and this week’s announcement by AbbVie that its JAK1 has been granted Breakthrough Therapy Designation by the FDA for atopic dermatitis. EXTON, Pa., January 10, 2018 /PRNewswire/ — On-going, independent research conducted by Spherix Global […]
Eli Lilly’s Taltz Now Approved for Psoriatic Arthritis, Bringing Key Competition for Rival IL-17 Inhibitor, Novartis’ Cosentyx
According to Spherix Global Insights’ RealTime Dynamix™: Psoriatic Arthritis quarterly series, US rheumatologists have become increasingly familiar with Taltz as a potential treatment for PsA and are primed to adopt the newest IL-17 agent into their PsA armamentarium. Download Report Overview EXTON, Pa., December 4, 2017 /PRNewswire/ — Eli Lilly’s IL-17 inhibitor, Taltz (ixekizumab), received […]
Recent Chart Audit Reveals Switching Rheumatoid Arthritis Patients to Roche/Genentech’s RoActemra (Actemra) is Significantly More Common in the EU5 than it is in the US
EU5 adoption of Pfizer’s Xeljanz and Eli Lilly’s Olumiant has been largely limited to rheumatologists practicing in Germany, according to a recently released independent report by Spherix Global Insights Download Report Overview EXTON, Pa., Nov. 21, 2017 /PRNewswire/ — Analysis of over 2,200 RA patients in the US and EU5 (France, Germany, Italy, Spain, and […]
US Rheumatologists Report that Use of Biologic/JAK Monotherapy in Rheumatoid Arthritis is Greatest for Pfizer’s Xeljanz, Roche/Genentech’s Actemra, and Sanofi/Regeneron’s Recently Launched Kevzara
Use of biologic/JAK monotherapy is primarily driven by adequate patient response on monotherapy, tolerability issues with traditional DMARDs, or comorbidities preventing use, according to recent findings from Spherix Global Insights Download Report Overview EXTON, Pa., October 23, 2017 /PRNewswire/ — Despite rheumatologists (n=102) reports of increased monotherapy over the past year, most feel that methotrexate […]
US Rheumatologists Teed Up for Rapid Adoption of BMS’ Orencia in Psoriatic Arthritis, Though the Real Game Changer Could Come with the Approval of Pfizer’s Xeljanz
Half of all surveyed rheumatologists agree a new oral small molecule would be of greater use in psoriatic arthritis than any additional alternative mechanism of action biologic, according to recent findings from Spherix Global Insights Download Report Overview EXTON, Pa., Oct. 20, 2017 /PRNewswire/ — At approximately three months post-launch, one-third of sampled rheumatologists (n=102) […]
